Samsung Biologics financials at a glance

+ Portfolio

The revenue of Samsung Biologics is reported as 3694.589 billion Won in the fiscal year 2023. The earnings were 12051 Won per share in 2023, which was 5.41 higher than 2022. And about 671.15786 billion Won are reported as free cash flow in the financials of Samsung Biologics 2023. No dividends were paid to the shareholders of the Samsung Biologics stock KOSE:A207940 in the financial year 2023.

₩3.69T

Revenue

₩12.05k

Earnings Per Share

48.57%

Gross Margin %

₩666.19B

Free Cash Flow

Revenue

3,694,589.00

Earnings Per Share

12,051.00

Gross Margin %

48.57

Free Cash Flow

666,191.44

Financials

Year	Year	TTM	2023	2022	2021	2020
Rev.	Revenue	N/A	₩3.69T	₩3.00T	₩1.57T	₩1.16T
GM %	Gross Margin %	48.16%	48.57%	48.67%	46.13%	35.51%
OM	Operating Margin	30.01%	30.14%	32.77%	34.27%	25.14%
EPS	Earnings Per Share	₩13.16k	₩12.05k	₩11.43k	₩5.95k	₩3.64k
Div.	Dividends	N/A	₩0.00	₩0.00	₩0.00	₩0.00
PR %	Payout Ratio %	0	0.00%	0.00%	0.00%	0
Sha.	Shares	N/AM	71.17M	71.17M	66.17M	66.17M
OCF	Operating Cash Flow	N/A	₩1.67T	₩953.05B	₩454.60B	₩202.09B
FCF	Free Cash Flow	N/A	₩666.19B	₩-3,791.89M	₩48.34B	₩62.43B
FCFS	Free Cash Flow Per Share	₩1.28k	₩7.88k	₩-,805.45	₩505.47	₩808.95

Samsung Biologics financials at a glance

Financials

Discover